Open, randomised phase III study assessing the toxicity and efficacy of platinum-based chemotherapy with vitamin supplementation in the treatment of lung cancer

ISRCTN ISRCTN87343655
DOI https://doi.org/10.1186/ISRCTN87343655
Secondary identifying numbers N/A
Submission date
11/11/2005
Registration date
24/11/2005
Last edited
03/03/2015
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Mary O'Brien
Scientific

Royal Marsden Hospital
Downs Road
Sutton
SM2 5PT
United Kingdom

Study information

Study designOpen randomised phase III trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleOpen, randomised phase III study assessing the toxicity and efficacy of platinum-based chemotherapy with vitamin supplementation in the treatment of lung cancer
Study acronymMVPV1
Study objectivesTo assess whether the addition of vitamin supplementation to chemotherapy may decrease treatment related toxicity and improve efficacy and outcome
Ethics approval(s)Approved by the Royal Marsden Hospital, 20/01/2006, ref: 05/Q0801/178
Health condition(s) or problem(s) studiedLung cancer
InterventionCisplatin-based chemotherapy +/- vitamin supplementation
Intervention typeMixed
Primary outcome measure1. Incidence of neutropenia
2. Incidence of mucositis
3. Incidence of emesis
Secondary outcome measures1. Disease response by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
2. Response rate
3. Overall survival
Overall study start date01/01/2006
Completion date01/01/2008

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants84
Key inclusion criteria1. Written informed consent
2. Male or female, aged over 18 years
3. Histologically or cytologically confirmed Non-Small Cell Lung Cancer (NSCLC), SCLC or mesothelioma: locally advanced or metastatic; where giving cisplatin 75 mg/m^2 is appropriate
4. Eastern Cooperative Oncology Group (ECOG): performance status (PS) zero to two
5. Lab requirements at entry: serum creatinine less that or equal to 1.25 Upper Limit of Normal (ULN), creatinine clearance more than 50 ml/min (Ethylene Diamine Tetra-acetic Acid [EDTA]) or more than 60 ml/min (C+G), white blood cell count (WBC) more than 3 x 10^9/l, neutrophils more than 1.5 x 10^9/l, platelets more than 100 x 10^9/l
6. Presence of at least one bi-dimensionally measurable index lesion
7. Effective contraception if indicated
8. Estimated life expectancy of at least 12 weeks
9. Patients are required to stop all complimentary medicines and prior vitamin supplements
Key exclusion criteria1. Pregnant or lactating women
2. Active infection
3. Inability or unwillingness to take vitamin supplementation
4. Serious systemic disorders incompatible with the study at the discretion of the investigator
Date of first enrolment01/01/2006
Date of final enrolment01/01/2008

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Royal Marsden Hospital
Sutton
SM2 5PT
United Kingdom

Sponsor information

Royal Marsden Hospital (UK)
Hospital/treatment centre

Downs Road
Sutton
SM2 5PT
England
United Kingdom

Website http://www.royalmarsden.org
ROR logo "ROR" https://ror.org/034vb5t35

Funders

Funder type

Government

Royal Marsden NHS Foundation Trust

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 11/12/2014 Yes No